Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 × NZW)F1 mice

Genes and Immunity

Volumn 8, Issue 8, 2007, Pages 653-662

  Jorgensen T N ^a   Roper, E ^a   Thurman, J M ^a   Marrack, P ^a,b   Kotzin, B L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BETA INTERFERON; BETA INTERFERON RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CONGENIC STRAIN; CONTROLLED STUDY; CROSS BREEDING; DISEASE MODEL; ENZYME INHIBITION; FEMALE; GENETIC CORRELATION; GENETIC SUSCEPTIBILITY; GLOMERULUS; IMMUNE COMPLEX DEPOSITION; INFLAMMATION; KIDNEY DISEASE; KIDNEY INJURY; LUPUS LIKE SYNDROME; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; SIGNAL TRANSDUCTION;

ANIMALS; B-LYMPHOCYTES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; INTERFERON-ALPHA; INTERFERON-BETA; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MICE; MICE, CONGENIC; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION;

ANAS; MUS;

EID: 36949003890     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364430     Document Type: Article

References (40)

1. Kotzin BL, West SG. Systemic Lupus Erythematosus. In: Rich R, Shearer WT, Kotzin BL, Schroeder Jr HW (eds). Clinical Immunology. Principles and Practice. Mosby International Limited: PA, 2001, pp 60.1-60.24.
2. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
3. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
4. Jorgensen TN, Thurman J, Izui S, Falta MT, Metzger TE, Flannery SA et al. Genetic susceptibility to PolyI:C-induced IFNα/β-dependent accelerated disease in lupus-prone mice. Genes Immun 2006; 7 555-567.
5. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha y identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-1503.
6. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-390.
7. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1-17.
8. Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G et al. Evidence for an interferon-inducible gene, IFi202, in the susceptibility to systemic lupus. Immunity 2001; 15: 435-443.
9. Vyse TJ, Drake CG, Rozzo SJ, Roper E, Izui S Kotzin BL. Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice. J Clin Invest 1996; 98: 1762-1772.
10. Gubbels MR, Jorgensen TN, Metzger TE, Menze K, Steele H, Flannery SA et al. Effects of MHC and gender on lupus-like autoimmunity in Nba2 congenic mice. J Immunol 2005; 175: 6190-6196.
11. Xie C, Zhou XJ, Liu X, Mohan C. Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum 2003; 48: 1080-1092.
12. Atencio S, Amano H, Izui S, Kotzin BL. Separation of the New Zealand Black genetic contribution to lupus from New Zealand Black determined expansions of marginal zone B nd B1a cells. J Immunol 2004; 172 4159-4166.
13. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen T, Deocharan B et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2080-2091.
14. Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA 2002; 99: 5545-5550.
15. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999; 189: 521-530.
16. Pramanik R, Jorgensen TN, Xin H, Kotzin BL, Choubey D. Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility. J Biol Chem 2004; 279: 16121-16127.
17. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-788.
18. Mathian A, Weinberg A, Gallegos M, Banchereau. J, Koutouzov S. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White)F1 but not in BALB/c mice. J Immunol 2005; 174 2499-2506.
19. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004; 173: 2134-2142.
20. Deocharan B, Qing X, Lichauco J, Putterman C. α-Actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002; 168: 3072-3078.
21. Xie C, Liang Z, Chang S, Mohan C. Use of a novel elution regimen reveals the dominance of polyreactive antinuclear autoantibodies in lupus kidneys. Arthritis Rheum 2003; 48, 2343-2352.
22. Kalaaji M, Sturfelt G, Mjelle J, Nossent H, Rekvig O. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis. Arthritis Rheum 2006; 54: 914-926.
23. Kalaaji M, Mortensen E, Jorgensen L, Olsen R, Rekvig O. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 2006, 168: 1779-1792.
24. Qing X, Zavadil J, Crosby M, Hogarth M, Hahn B, Mohan C et al. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/Ipr mouse glomerular mesangial cells. Arthritis Rheum 2006; 54: 2198-2210.
25. Patole PS, Grone HJ, Segerer S, Ciubar R, Belemezova E, Henger A et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-Like Receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005, 16: 1326-1338.
26. Satoh J, Nanri Y, Tabunoki H, Yamamura T. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: An implication for IFNβ-related adverse effects in multiple sclerosis. BMC Neurol 2006; 6: 18-34.
27. Perez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine hipus nephritis. J Am Soc Nephrol 2001; 12: 1369-1382.
28. Dai C, Liu Z, Zhou H, Li L. Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulo-interstitial lesions in patients with lupus nephritis. Chin Med J (England) 2001; 114: 864-868.
29. Luzina I, Atamas S, Storrer C, daSilva L, Kelsoe G, Papadimitriou J et al. Spontaneous formation of germinal centers in autoimmune mice. J Leukoc Biol 2001; 70: 578-584.
30. Connolly K, Roubinian JR, Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoinimunity. J Immunol 1992; 149: 3083-3088.
31. Adachi Y, Inaba M, Sugihara A, Koshiji M, Sugiura K, Amoh Y et al. Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW x BXSB)F1 mice. Immunobiology 1998; 198: 451-464.
32. Mohan C, Yu Y, Morel L, Yang P, Wakeland EK. Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J Immunol 1999; 162: 6492-6502.
33. Stohl W, Xu D, Metzger TE, Kim KS, Morel L, Kotzin BL. Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice. Arthritis Rheum 2004; 50: 2227-2239.
34. Wang H, Chatterjee G, Meyer JJ, Liu CJ, Manjunath NA, Bray-Ward P et al. Characteristics of three homologous 02 genes (Ifi202a, IFi202b, and Ifi202c) from the murine interferon-activatable gene 200 cluster. Genomics 1999; 60: 281-294.
35. Trapani JA, Browne KA, Dawson MJ, Ramsay RG, Eddy RL, Show TB et al. A novel gene constitutively expressed in human lymphoid cells is inducible with interferon-gamma in myeloid cells. Immunogenetics 1992; 36: 369-376.
36. Choubey D, Lengyel P. Binding of an interferon-inducible protein (p202) to the retinoblastoma protein. J Biol Chem 1995; 270: 6134-6140.
37. D'Souza. S, Xin H, Walter S, Choubey D. The gene encoding p202, an interferon-inducible negative regulator of the p53 tumor suppressor, is a target of p53-mediated transcriptional repression, J Biol Chem 2001; 276: 298-305.
38. Xin H, D'Souza S, Jorgensen TN, Vaughan AT, Lengyel P, Kotzin BL et al. Increased expression of Ifi202, an IFN-activatable gene, in B6.Nba2 lupus susceptible mice inhibits p53-mediated apoptosis. J Immunol 2006; 176: 5863-5870.
39. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264: 1918-1921.
40. Vyse TJ, Rozzo SJ, Drake CG, Izui S, Kotzin BL. Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. J Immunol 1997; 158: 5566-5574.